Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)

Market Cap	5.11B
Revenue (ttm)	1.24B
Net Income (ttm)	410.38M
Shares Out	n/a
EPS (ttm)	0.53
PE Ratio	12.45
Forward PE	n/a
Dividend	0.23 (7.90%)
Ex-Dividend Date	Jun 25, 2025

Volume	498,500
Average Volume	227,905
Open	2.970
Previous Close	2.980
Day's Range	2.960 - 3.090
52-Week Range	1.990 - 3.090
Beta	n/a
RSI	83.14
Earnings Date	Aug 15, 2025

About SGX:T14

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and preparations, and nutritional supplements. In addition, the company is involved in pharmaceutical and drug retail business. Further, it offers Suxiao ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 4,619
• Stock Exchange: Singapore Exchange
• Ticker Symbol: T14

Financial Performance

In 2024, SGX:T14's revenue was 7.31 billion, a decrease of -11.14% compared to the previous year's 8.22 billion. Earnings were 2.23 billion, an increase of 125.94%.

Financial numbers in CNY